Product Name:
MEF2C-pS396
Product Number:
ab-pn623
Target Full Name: Myocyte-specific enhancer factor 2C
Target Alias: Myocyte-specific enhancer factor 2C: Myocyte-specific enhancer factor 2C: Myocyte-specific enhancer factor 2C
Product Type Specific: MEF2C phosphosite-specific antibody
Antibody Code: PN623
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S396
Protein UniProt: Q06413
Protein SigNET: MEF2C
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human MEF2C
Antibody Immunogen Sequence: SEPV(pS)PPRD(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues S392 to D400. S396 phosphorylation induces MEF2C transcriptional activity and facilitates its sumoylation at K391, which in turn recruits co-repressors to inhibit transcription. This is one of the less major in vivo phosphorylation sites in MEF2C (≥8 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). MEF2C is known to be phosphorylated at this site in vitro by CDK1 (CDC2).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.75 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus macaque | Dog | Rat | Mouse | Platypus | Zebra fish | Fruit fly.
Related Product 1: MEF2A T108 phosphorylation antibody (Cat. No.: AB-PN622)
Related Product 2: MEF2D S121 phosphorylation antibody (Cat. No.: AB-PN624)
Related Product 3: MEF2D S180 phosphorylation antibody (Cat. No.: AB-PN625)
Scientific Background: MEF2C (Myocyte-specific enhancer factor 2C) is a transcription activator that belongs to the MADS-box family. It binds specifically to the MEF2 element present in the regulatory regions of many muscle-specific genes. It is essential for proper muscle development, cardiac morphogenesis and myogenesis, neuronal differentiation, and brain maturation. It acts as a molecular switch, regulating genes involved in cardiac, skeletal muscle, and neuronal function, as well as synaptic density, which impacts learning and memory. It enhances transcriptional activation mediated by SOX18. It functions in hippocampal-dependent learning and memory by suppressing the number of excitatory synapses and thus regulating basal and evoked synaptic transmission. It is crucial for normal neuronal development, distribution, and electrical activity in the neocortex. It is necessary for proper development of megakaryocytes and platelets and for bone marrow B-lymphopoiesis. It is required for B-cell survival and proliferation in response to BCR stimulation, efficient IgG1 antibody responses to T-cell-dependent antigens and for normal induction of germinal center B-cells. It is likely involved in neurogenesis and in the development of cortical architecture. It is often regulated by other transcription factors and can be affected by microRNAs (e.g., MIRN21). Isoforms that lack the repressor domain are more active than isoform 1. It is expressed in brain and skeletal muscle. Mutations in MEF2C are associated with severe neurodevelopmental disorders, such as the 5q14.3 deletion syndrome (MEF2C-related disorder), intellectual disability, autism, schizophrenia, and Alzheimer’s disease. This description may include information annotated by UniProt and/or Google AI.